Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same

Patent metadata

Field	Value
Publication number	US-10155795-B2
Application number	US-201414776516-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1α). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.

First claim

What is claimed is:

1. A therapeutic comprising a nucleic acid molecule comprising a nucleotide sequence encoding an Immunoglobulin E (IgE) leader sequence and hypoxia inducible factor-1 alpha (HIF+1α), wherein said nucleic acid molecule comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NO:3, and SEQ ID NO:5.

2. The therapeutic of claim 1 , further comprising a pharmaceutically acceptable excipient.

3. A method of treating hypoxia or ischemia in a subject in need thereof, the method comprising administering the therapeutic of claim 1 to the subject.

4. The method of claim 3 , wherein administering the therapeutic includes electroporation.

5. The method of claim 3 , wherein administering the therapeutic includes at least one of intramuscular administration and intradermal administration.

6. The method of claim 3 , wherein the hypoxia or ischemia is associated with critical limb ischemia, peripheral artery disease, wound healing, a vascular disease, a circulatory disease, coronary artery disease, cardiovascular disease, or diabetes.

7. The method of claim 6 , wherein the hypoxia or ischemia is associated with critical limb ischemia.

8. The method of claim 3 , wherein at least one of capillary density, collateral vessel formation or vessel size is increased in the subject administered the therapeutic as compared to a subject not administered the therapeutic.

9. The method of claim 3 , wherein tissue perfusion is increased in the subject administered the therapeutic as compared to a subject not administered the therapeutic.

10. The method of claim 3 , wherein tissue necrosis is decreased in the subject administered the therapeutic as compared to a subject not administered the therapeutic.

11. A nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: the nucleotide sequence of SEQ ID NO:5, and the nucleotide sequence of SEQ ID NO:3, wherein said nucleic acid molecule further comprises a nucleotide sequence comprising encoding an Immunoglobulin E (IgE) leader sequence.

12. The nucleic acid molecule of claim 11 , wherein the nucleotide sequence is a plasmid.

Assignees

• Weiner David B
• Muthumani Karuppiah
• Mohler Emile
• Ouma Geoffrey
• Univ Pennsylvania

Inventors

• Weiner David B
• Muthumani Karuppiah
• Mohler Emile
• Ouma Geoffrey

Classifications

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• A61K41/0047

  Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent · CPC title

• C07H21/04

  with deoxyribosyl as saccharide radical · CPC title

• C07K14/4702 Primary

  Regulators; Modulating activity · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title